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Introduction {#sec1}
============

Respiratory viruses are the leading cause of respiratory tract infection [@bib1], [@bib2]. Influenza virus and respiratory syncytial virus have been associated with high morbidity and mortality [@bib3], [@bib4], [@bib5]. Rhinovirus has been found to be the most frequently detected respiratory virus among patients with community-acquired pneumonia, and has been associated with significant morbidity and mortality [@bib1], [@bib6], [@bib7], [@bib8]. Adenovirus and parainfluenza virus (PIV) were reported to have the highest hospitalization--fatality ratio [@bib9].

Defining of the burden of respiratory viruses is one of the agendas in the WHO Battle against Respiratory Viruses (BRaVe) initiative [@bib10]. Accurate data on the burden of respiratory virus infection is critical for patient management, infection control measures and public health policies. Current clinical guidelines suggest that respiratory virus should be tested in patients with respiratory symptoms, or those with myocarditis or encephalitis [@bib2]. As a result, epidemiological data on respiratory virus infection mostly rely on studies analysing patients with clinical evidence of respiratory tract infection [@bib1], [@bib9], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15]. However, non-respiratory symptoms and extrapulmonary complications are common among patients with respiratory virus infection [@bib15], [@bib16], [@bib17], [@bib18]. Renal failure is particularly common among patients with Middle East respiratory syndrome coronavirus infection [@bib19], [@bib20]. Myocardial infarction and stroke can be triggered by respiratory virus infection [@bib12], [@bib14], [@bib21]. Hence, epidemiological studies excluding patients without symptoms or signs of respiratory tract infection may underestimate the true burden of respiratory virus infection.

Here, our objective was to reveal the hidden burden of respiratory virus infection among patients requiring hospitalization without clinical suspicion of respiratory virus infection. We explored the differences in the incidence of different respiratory viruses between patients with or without clinical suspicion of respiratory tract infection. We analysed the clinical features associated with the detection of respiratory viruses among patients without fever or respiratory symptoms. To reduce patient discomfort, we collected saliva specimens for respiratory virus testing. We and others have demonstrated that there is a high concordance (\>90%) between saliva and nasopharyngeal specimens in the detection of respiratory viruses [@bib22], [@bib23], [@bib24].

Methods {#sec2}
=======

Study setting and design {#sec2.1}
------------------------

This was a prospective cohort study conducted in Queen Mary Hospital of Hong Kong, an acute-care university-affiliated teaching hospital with 1700 beds. All adult patients admitted to the acute medical wards from 9 January to 12 February, 2018 were screened for eligibility. Inclusion criteria were age ≥18 years, admission to any hospitals for \<24 hours, competent and agreed to provide written informed consent. Patients were excluded if they could not provide adequate saliva. Written informed consent was obtained from all recruited patients. Saliva specimens were collected from all eligible patients.

Eligible patients with fever ≥38.0°C or any respiratory symptoms (RS) upon admission were classified as the fever/RS group, whereas those without fever or respiratory symptoms in the preceding 7 days before hospitalization were classified as non-fever/RS group. Respiratory symptoms included runny nose, sore throat, cough (including haemoptysis), sputum and shortness of breath. A saliva specimen was collected from all eligible patients. Each patient in the fever/RS group was matched with an age-matched (within 5 years) and sex-matched patient in the non-fever/RS group in a 1:1 ratio. All unmatched patients were excluded from further testing.

Saliva specimens were tested for respiratory viruses using NxTAG™ Respiratory Pathogen Panel IVD (Luminex, Austin, TX, USA) as described previously [@bib22], [@bib25]. Differentiation of rhinovirus and enterovirus was performed by sequence analysis of the VP4/VP2 gene region.

Data on fever or respiratory symptoms were collected by research nurses using a standardized questionnaire. Final diagnosis, outcome and laboratory investigation results were obtained from the Clinical Management System.

This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW 13-265). This study is reported using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [@bib26]. Please refer to Supplementary material ([Appendix S1](#appsec1){ref-type="sec"})for details on respiratory virus testing and sequencing, and specimen collection.

Statistical analysis {#sec2.2}
--------------------

All statistical analysis was performed using SPSS 23.0. Mann--Whitney *U* test and Fisher\'s exact test were used for the comparison of continuous variables or categorical variables, respectively. A p value \< 0.05 was considered statistically significant. The sample size chosen was based on feasibility.

Results {#sec3}
=======

Patient characteristics {#sec3.1}
-----------------------

A total of 385 patients were included in the study, and 214 patients were included for respiratory virus testing in their saliva and final analysis, including 107 patients in the fever/RS group and 107 age- and sex-matched patients in the non-fever/RS group ([Table 1](#tbl1){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"} ). The median age was 67.5 years (range 18--93 years), and 42.1% (90/214) were female. There was no significant difference in the demographics and co-morbidities between the fever/RS group and the non-fever/RS group, except that chronic lung disease was more common among the fever/RS group than the non-fever/RS group (25.2% (27/107) versus 6.5% (7/107); p \< 0.001). The number of patients in each week was not statistically different between the fever/RS group and the non-fever/RS group (p 0.489) (see [Supplementary material, Table S1](#appsec1){ref-type="sec"}).Table 1Demographics, clinical features and outcomes of all 214 patientsTable 1Fever/RS group (*n* = 107)Non-fever/RS group (*n* = 107)p valueDemographics Median age in years (range)69 (18--92)66 (19--93)0.411 Female45 (42.1)45 (42.1)1.000Underlying disease Hypertension51 (47.7)57 (53.3)0.494 Chronic heart disease33 (30.8)31 (29.0)0.881 Chronic lung disease27 (25.2)7 (6.5)\<0.001 Chronic liver disease14 (13.1)6 (5.6)0.098 Chronic kidney disease12 (11.2)15 (14.0)0.681 Neurological conditions13 (12.1)15 (14.0)0.840 Peripheral vascular disease4 (3.7)2 (1.9)0.683 Diabetes mellitus31 (29.0)31 (29.0)1.000 Thyroid disease6 (5.6)5 (4.7)1.000 Other endocrine or metabolic disorders7 (6.5)10 (9.3)0.614 Gout or pseudogout3 (2.8)6 (5.6)0.498 Autoimmune disease6 (5.6)5 (4.7)1.000 Solid organ malignancy19 (17.8)13 (12.1)0.338 Haematological malignancy6 (5.6)5 (4.7)1.000 Transplant recipient0 (0)2 (1.9)0.498Respiratory symptoms or fever upon admission Cough66 (61.7)0 (0)\<0.001 Fever50 (46.7)0 (0)\<0.001 Sputum42 (39.3)0 (0)\<0.001 Shortness of breath35 (32.7)0 (0)\<0.001 Runny nose33 (30.8)0 (0)\<0.001 Sore throat19 (17.8)0 (0)\<0.001Non-respiratory presenting symptoms/reason for hospital admission Chest discomfort24 (22.4)29 (27.1)0.527 Palpitation or arrhythmia8 (7.5)19 (17.8)0.038 Limb oedema11 (10.3)8 (7.5)0.632 High blood pressure0 (0)4 (3.7)0.121 Syncope4 (3.7)9 (8.4)0.252 Seizure1 (0.9)4 (3.6)0.369 Dizziness14 (13.1)22 (20.6)0.200 Numbness or weakness3 (2.8)10 (9.3)0.082 Headache2 (1.9)3 (2.8)1.000 Confusion2 (1.9)1 (0.9)1.000 Gastrointestinal symptoms[a](#tbl1fna){ref-type="table-fn"}28 (26.2)20 (18.7)0.251 Complications of endocrine disorders[b](#tbl1fnb){ref-type="table-fn"} or electrolyte disturbance4 (3.7)6 (5.6)0.748 Trauma0 (0)4 (3.7)0.121Cardiac or neurological complications Hypertension complications1 (0.9)6 (5.6)0.119 Myocardial infarction or angina3 (2.8)3 (2.8)1.000 Arrhythmia5 (4.7)11 (10.3)0.193 Stroke/transient ischaemic attack1 (0.9)8 (7.5)0.035Outcome Require oxygen supplement27 (25.2)4 (3.7)[c](#tbl1fnc){ref-type="table-fn"}\<0.001 ICU or CCU admission0 (0)2 (1.8)0.498 Death0 (0)1 (0.9)1.000[^2][^3][^4][^5][^6]Fig. 1Recruitment flow chart.Fig. 1Fig. 2Comparison of the detection of respiratory viruses between the fever/respiratory symptom (RS) group and the non-fever/RS group. \*p \< 0.05; \*\*\*p \< 0.001.Fig. 2

Among the fever/RS group, the most common respiratory symptom was cough (61.7%; 66/107) ([Table 1](#tbl1){ref-type="table"}). Sixteen patients (15.0%) only had fever but no respiratory symptoms. Among patients in the non-fever/RS group, the most common symptom was chest discomfort (27.1%; 29/107), followed by dizziness (20.6%; 22/107) and gastrointestinal symptoms (18.7%; 20/107) ([Table 1](#tbl1){ref-type="table"}). Three patients in the non-fever/RS group developed fever (*n* = 2) or respiratory symptoms (*n* = 1) during hospitalization after collection of saliva. There was no significant difference in the frequency of non-respiratory symptoms between the fever/RS group and the non-fever/RS group, except that palpitation was significantly more common in the non-fever/RS group (17.8% (19/107) versus 7.5% (8/107); p 0.038). Significantly more patients in the fever/RS group required oxygen supplementation when compared with those in the non-fever/RS group (25.2% (27/107) versus 3.7% (4/107); p \< 0.001). Oseltamivir was only given empirically in the fever/RS group, not in the non-fever/RS group.

Respiratory virus detection by multiplex molecular assay {#sec3.2}
--------------------------------------------------------

Respiratory viruses were detected in 34.1% (73/214) of patients ([Table 2](#tbl2){ref-type="table"} ; and see [Supplementary material, Table S2](#appsec1){ref-type="sec"}). The respiratory virus detection rate in the fever/RS group (44.9%; 48/107) was significantly higher than that in the non-fever/RS group (23.4%; 25/107) (p 0.001). For the 16 patients with fever only in the fever/RS group, seven (43.8%) had respiratory virus detected. Co-infection with two or more respiratory viruses was detected in 17 patients, including 10.3% (11/107) in the fever/RS group and 5.6% (6/107) in the non-fever/RS group, but the difference was not statistically significant (p 0.312). There was no significant difference in the proportion of patients with co-infection among different respiratory viruses (see [Supplementary material, Fig. S1](#appsec1){ref-type="sec"}).Table 2Comparison of respiratory virus detection between the fever/RS group and the non-fever RS group. Saliva specimens were tested for respiratory viruses by multiplex PCR[a](#tbl2fna){ref-type="table-fn"}Table 2VirusAll patients (*n* = 214)Fever/RS group (*n* = 107)Non-fever/RS group (*n* = 107)p valueAny virus detected73 (34.1)48 (44.9)25 (23.4)0.001Influenza virus19 (8.9)17 (15.9)2 (1.9)\<0.001 Influenza A[b](#tbl2fnb){ref-type="table-fn"}3 (1.4)2 (1.9)[c](#tbl2fnc){ref-type="table-fn"}1 (0.9)[d](#tbl2fnd){ref-type="table-fn"}1 Influenza B17 (7.9)16 (15.0)1 (0.9)\<0.001Adenovirus17 (7.9)6 (5.6)11 (10.3)0.312Any PIV17 (7.9)6 (5.6)11 (10.3)0.312 PIV-11 (0.5)1 (0.9)0 (0)1 PIV-20 (0)0 (0)0 (0)NA PIV-32 (0.9)1 (0.9)1 (0.9)1 PIV-4A1 (0.5)1 (0.9)0 (0)1 PIV-4B13 (5.9)3 (2.8)10 (9.3)0.082Rhinovirus/enterovirus[e](#tbl2fne){ref-type="table-fn"}16 (7.5)13 (12.1)3 (2.8)0.017Human metapneumovirus13 (6.1)9 (8.4)4 (3.7)0.252 Any coronaviruses6 (2.8)6 (5.6)0 (0)0.029 Coronavirus 229E1 (0.5)1 (0.9)0 (0)1 Coronavirus NL633 (1.4)3 (2.8)0 (0)0.246 Coronavirus OC432 (0.9)2 (1.9)0 (0)0.498 Coronavirus HKU10 (0)0 (0)0 (0)1Any RSV2 (0.9)1 (0.9)1 (0.9)[f](#tbl2fnf){ref-type="table-fn"}1.000 RSV-A2 (0.9)1 (0.9)1 (0.9)[f](#tbl2fnf){ref-type="table-fn"}1.000 RSV-B0 (0)00NABocavirus0 (0)0 (0)0 (0)NAMore than one respiratory virus detected17 (7.9)11 (10.3)6 (5.6)0.312[^7][^8][^9][^10][^11][^12][^13][^14]

Overall, the most frequently detected respiratory viruses were adenovirus (7.9%; 17/214) and influenza B virus (7.9%; 17/214) ([Table 2](#tbl2){ref-type="table"}, and see [Supplementary material, Fig. S1](#appsec1){ref-type="sec"}). For the fever/RS group, the most frequently detected respiratory viruses were influenza B virus (15.0%; 16/107) and enterovirus/rhinovirus (12.1%; 13/107) ([Table 2](#tbl2){ref-type="table"}). For the non-fever/RS group, the most frequently detected viruses were adenovirus (10.3%; 11/107) and PIV-4B (9.3%; 10/107). The detection rates of influenza B virus (15.0% (16/107) versus 0.9% (1/107), p \< 0.001), enterovirus/rhinovirus (12.1% (13/107) versus 2.8% (3/107); p 0.017) and coronaviruses (5.6% (6/107) versus 0% (0/107); p 0.029) were significantly higher in the fever/RS group than in the non-fever/RS group ([Fig. 2](#fig2){ref-type="fig"}). Adenovirus (10.3% (11/107) versus 5.6% (6/107); p 0.312) and PIV-4B (9.3% (10/107) versus 2.8% (3/107); p 0.082) were more common in the non-fever/RS group than in the fever/RS group, but not reaching statistical significance.

We have further compared patients with and without virus detection among patients in the non-fever/RS group ([Table 3](#tbl3){ref-type="table"} ). For co-morbidities, there were no significant differences between patients with respiratory virus detected than those without respiratory virus detected. None of the patients in the non-fever/RS group with respiratory virus detected had new chest radiograph changes suggestive of pneumonia. Chest discomfort was significantly more common among patients with respiratory virus detected than those without respiratory virus detected (44% (11/25) versus 22% (18/82); p 0.040). Adenovirus (20.7%) and PIV-4B (17.2%) were the most common respiratory viruses detected in patients with chest discomfort (see [Supplementary material, Table S3](#appsec1){ref-type="sec"}).Table 3Comparison between patients with or without respiratory virus detected in the non-fever/RS groupTable 3Respiratory virus detected (*n* = 25)No respiratory virus detected (*n* = 82)p valueDemographics Median age in years (range)70 (39-93)64 (19-91)0.656 Female15 (60.0)47 (57.3)1.000Underlying disease Hypertension13 (52.0)44 (53.7)1.000 Chronic heart disease10 (40.0)21 (25.6)0.209 Chronic lung disease1 (4.0)6 (7.3)1.000 Chronic liver disease2 (8.0)4 (4.9)0.623 Chronic kidney disease3 (12.0)12 (14.6)1.000 Neurological conditions1 (4.0)14 (17.1)0.184 Peripheral vascular disease1 (4.0)1 (1.2)0.414 Diabetes mellitus4 (16.0)27 (32.9)0.133 Thyroid disease2 (8.0)3 (3.7)0.332 Other endocrine disorders1 (4.0)9 (11.0)0.447 Gout or pseudogout1 (4.0)5 (6.1)1.000 Autoimmune disease2 (8.0)3 (3.7)0.332 Solid organ malignancy2 (8.0)11 (13.4)0.728 Haematological malignancy1 (4.0)4 (4.9)1.000 Transplant recipient1 (4.0)1 (1.2)0.414Clinical features at presentation Chest discomfort11 (44.0)18 (22.0)0.040 Palpitation/arrhythmia5 (20.0)14 (17.1)0.768 Limb oedema1 (4.0)7 (8.5)0.678 High blood pressure2 (8.0)2 (2.4)0.232 Syncope2 (8.0)7 (8.5)1.000 Seizure0 (0)4 (4.9)0.571 Dizziness6 (24.0)16 (19.5)0.587 Numbness/weakness1 (4.0)9 (11.0)0.447 Headache0 (0)3 (3.7)1.000 Confusion0 (0)1 (1.2)1.000 Gastrointestinal symptoms3 (12.0)17 (20.7)0.395 Endocrine or electrolyte disturbance1 (4.0)5 (6.1)1.000 Trauma0 (0)4 (4.9)0.571Initial laboratory findings, median (interquartile range) Total white blood cell count, × 10^9^ cells/L7.0 (5.8--8.5)7.1 (6.0--9.0)0.941 Neutrophil count, × 10^9^ cells/L4.7 (3.2--5.7)4.6 (3.9--6.7)0.397 Lymphocyte count, × 10^9^ cells/L1.64 (1.18--2.15)1.47 (1.04--1.96)0.383 Platelet count, × 10^9^ cells/L226 (187--251)206 (177--285)0.924Final diagnosis Myocardial infarction or angina1 (4.0)2 (2.4)0.554 Arrhythmia4 (16.0)7 (8.5)0.279 Stroke/transient ischaemic attack1 (4.0)7 (8.5)0.678 Poorly controlled hypertension2 (8.0)4 (4.9)0.623Outcome Require oxygen supplement2 (8.0)2 (2.4)0.232 ICU or CCU admission0 (0)2 (2.4)1.000 Death0 (0)1 (1.2)1.000[^15][^16]

Discussion {#sec4}
==========

Principal findings {#sec4.1}
------------------

This study showed that respiratory viruses could be frequently detected among acutely hospitalized patients without fever or respiratory symptoms (23.4%), although less frequently than in patients with fever or respiratory symptoms (44.9%). For the fever/RS group, influenza B virus and enterovirus/rhinovirus were the most commonly identified viruses, which was similar to the surveillance data from the Public Health Laboratory Service in Hong Kong during the same period (see [Supplementary material, Fig. S2](#appsec1){ref-type="sec"}). However, for the non-fever/RS group, adenovirus and PIV-4B were the most frequently detected viruses. Notably, adenovirus and PIV-4B were more common among patients in the non-fever/RS group than those in the fever/RS group. Among patients in the non-fever/RS group, chest discomfort was more frequently reported by patients with respiratory virus detected than those without respiratory virus detected.

Comparison with other studies {#sec4.2}
-----------------------------

Previous studies have reported that respiratory symptoms predominated in patients with symptomatic infection, whereas non-respiratory symptoms were only present in a minority of patients [@bib7], [@bib15]. Many retrospective studies have demonstrated an association between respiratory virus infection and extrapulmonary complications [@bib12], [@bib14], [@bib21]. However, because of the bias in testing patients with fever or respiratory symptoms, these reported results may not be accurate. Our results suggest that patients without respiratory symptoms should be enrolled in future studies on the role of respiratory viruses in extrapulmonary complications.

Adenovirus and PIV-4B were more frequently detected in the non-fever/RS group than in the fever/RS group. Adenovirus and PIV are generally perceived to be less important than influenza virus or respiratory syncytial virus because of the low incidence. However, a retrospective study showed that adenovirus and PIV had the highest hospitalization--fatality rate among different respiratory viruses [@bib9]. It is possible that these respiratory viruses are transient, colonizing the patients\' upper respiratory tract but not actually causing the symptoms or disease. However, although asymptomatic infections due to adenovirus and PIV are often found in children [@bib11], [@bib27], [@bib28], adenovirus and PIV are rarely detected among healthy asymptomatic adults [@bib11], [@bib29].

This study was designed to minimize potential bias. First, we have recorded the respiratory symptom data from study participants using a standardized questionnaire. This is important because mild symptoms may not be actively reported by patients. Second, the fever/RS group and non-fever/RS group were matched for age and sex. The matching of age is particularly important because previous studies have shown that the proportion of patients with symptoms varies according to age [@bib28]. Another unique feature in this study is that we have included patients with fever but without respiratory symptoms in the fever/RS group because many clinicians test respiratory viruses in febrile patients without respiratory symptoms.

In the current study, patients in the non-fever/RS group were admitted to hospital for acute non-respiratory symptoms. Hence, our patient cohort differs from studies involving asymptomatic adult individuals who were not clinically affected by the respiratory viruses [@bib11], [@bib27], [@bib29]. Further studies are required to determine whether there is a causal relationship between the identified respiratory virus and the symptoms among patients in the fever/RS group.

This study was conducted during the influenza B epidemic. As expected, influenza B virus was the most commonly detected respiratory virus among the fever/RS group. Interestingly, influenza B virus was only found in one patient in the non-fever/RS group. The ratio in the detection rate of influenza B virus in the fever/RS group and non-fever/RS group was greatest among all viruses. Our results suggest that patients with influenza B virus infection are more likely to present with respiratory symptoms than those with other respiratory virus infections.

Limitations of this study {#sec4.3}
-------------------------

First, we only recruited patients from acute adult medical wards. Therefore, adult patients hospitalized with surgical conditions or paediatric patients would not be included. Second, we enrolled patients within 24 hours of hospitalization. The role of respiratory viruses for nosocomial complications should be further explored. Third, this study was conducted over a 1-month period during the influenza B winter season, and therefore the respiratory viruses detected in this study are not representative for the entire year. A long-term study should be conducted to capture the peak seasons of other respiratory viruses. Fourth, some patients in the non-fever/RS group may have prolonged viral shedding from a previous respiratory illness that occurred more than 7 days before admission. Finally, we studied acutely hospitalized patients, who would have more severe symptoms or complications when compared with patients seeking help in the community. Therefore, further studies should be performed at general practice in the community.

Conclusions and implications for clinical practice and research studies {#sec4.4}
=======================================================================

This study showed that respiratory viruses, especially non-influenza viruses, can be detected in a substantial proportion of acutely hospitalized adult patients without clinically apparent respiratory tract infection. For future studies, the inclusion of hospitalized patients without clinically apparent respiratory tract infection will lead to a better understanding of the non-respiratory symptomatology and extrapulmonary complications of respiratory viruses.

The high rate of detection of respiratory viruses among the non-fever/RS group may be important for infection control and clinical management. Respiratory viruses are responsible for many nosocomial outbreaks. Patients without clinical evidence of respiratory illness may represent an 'occult' source of respiratory viruses for nosocomial outbreaks, and therefore these patients might have to be included in outbreak investigations. Furthermore, the detection of respiratory viruses in these patients may affect antiviral treatment decisions, especially when novel antivirals against non-influenza viruses become available [@bib6], [@bib30].
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[^1]: K.K.W. To and K.-H. Chan contributed equally.

[^2]: Abbreviations: CCU, coronary care unit; ICU, intensive care unit.

[^3]: Data expressed as *n* (%) unless otherwise stated.

[^4]: Gastrointestinal symptoms include nausea, bloating sensation, vomiting, diarrhoea, constipation, dysphagia and abdominal pain.

[^5]: Complications of endocrine disorders include hypoglycaemia and thyroid storm.

[^6]: Required oxygen supplementation after hospitalization.

[^7]: Abbreviations: NA, not applicable; PIV, parainfluenza virus; RS, respiratory symptom; RSV, respiratory syncytial virus.

[^8]: Data expressed as *n* (%).

[^9]: Multiplex PCR was performed using NxTAG™ RPP IVD.

[^10]: Either influenza A, H1 or H3 positive by NxTAG™ RPP IVD.

[^11]: Both were influenza A virus subtype H3.

[^12]: Influenza A virus subtype H1.

[^13]: Rhinovirus and enterovirus cannot be differentiated with NxTAG™ RPP IVD. Differentiation of rhinovirus and enterovirus was achieved by sequence analysis of the VP4/VP2 region. Out of 16 specimens, VP4/VP2 sequencing was successful for nine specimens in the fever/RS group. Rhinovirus A, B and C were detected in three, one and five specimens, respectively.

[^14]: This patient developed fever during hospitalization after the collection of the saliva specimen.

[^15]: Abbreviations: CCU, coronary care unit; ICU, intensive care unit.

[^16]: Data expressed as *n* (%) unless otherwise stated.
